Imaging Applications to Parkinson's Disease Clinical Trials

Imaging in Parkinson's Disease

Volumn , Issue , 2011, Pages

  Niethammer, Martin ^a   Feigin, Andrew ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Beta cit spect; Biomarker; Clinical trials; Fdopa PET; Neuroimaging; Parkinson's disease; Treatment outcome

Indexed keywords

EID: 84921258450     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780195393484.003.0119     Document Type: Chapter

References (69)

1. Ahlskog, J. E., and R. J. Uitti. 2010. Rasagiline, Parkinson neuroprotection, and delayed-start trials: Still no satisfaction? Neurology 74:1143-8.
2. Anik, Y., P. Iseri, A. Demirci, S. Komsuoglu, and N. Inan. 2007. Magnetization transfer ratio in early period of Parkinson disease. Acad Radiol 14:189-92.
3. Asanuma, K., C. Tang, Y. Ma, V. Dhawan, P. Mattis, C. Edwards et al. 2006. Network modulation in the treatment of Parkinson's disease. Brain 129:2667-78.
4. Bartels, A. L., A. T. Willemsen, J. Doorduin, E. F. de Vries, R. A. Dierckx, and K. L. Leenders. 2010. [11C]-PK11195 PET: Quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Relat Disord 16:57-9.
5. Benabid, A. L., A. Koudsie, A. Benazzouz, L. Vercueil, V. Fraix, S. Chabardes et al. 2001. Deep brain stimulation of the corpus luysi (subthalamic nucleus) and other targets in Parkinson's disease Extension to new indications such as dystonia and epilepsy. J Neurol 248 (Suppl 3): III37-47.
6. Benabid, A. L., P. Pollak, A. Louveau, S. Henry, and J. de Rougemont. 1987. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 50:344-6.
7. Biomarkers Definitions Working Group. 2001. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89-95.
8. Burack, M. A., J. Hartlein, H. P. Flores, L. Taylor-Reinwald, J. S. Perlmutter, and N. J. Cairns. 2010. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 74:77-84.
9. Christine, C. W., P. A. Starr, P. S. Larson, J. L. Eberling, W. J. Jagust, R. A. Hawkins, et al. 2009. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73:1662-9.
10. De Gruttola, V. G., P. Clax, D. L. DeMets, G. J. Downing, S. S. Ellenberg, L. Friedman, et al. 2001. Considerations in the evaluation of surrogate endpoints in clinical trials Summary of a National Institutes of Health workshop. Control Clin Trials 22:485-502.
11. Deuschl, G., C. Schade-Brittinger, P. Krack, J. Volkmann, H. Schafer, K. Botzel et al. 2006. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 355:896-908.
12. Dhawan, V., and D. Eidelberg D. 2006. PET imaging in Parkinson's disease and other neurodegenerative disorders. In The neurobiology of disease, ed. S. Gilman, 821-28. San Diego: Academic Press.
13. Eberling, J. L., W. J. Jagust, C. W. Christine, P. Starr, P. Larson, K. S. Bankiewicz et al. 2008. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70:1980-3.
14. Eckert, T., A. Barnes, V. Dhawan, S. Frucht, M. F. Gordon, A. S. Feigin et al. 2005. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 26:912-21.
15. Eckert, T., M. Sailer, J. Kaufmann, C. Schrader, T. Peschel, N. Bodammer et al. 2004. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage 21:229-35.
16. Eerola J., P. J. Tienari, S. Kaakkola, P. Nikkinen, and J. Launes. 2005. How useful is [123I]beta-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry 76:1211-6.
17. Eidelberg, D. 2009. Metabolic brain networks in neurodegenerative disorders: A functional imaging approach. Trends Neurosci 32:548-57.
18. Fahn, S., D. Oakes, I. Shoulson, K. Kieburtz, A. Rudolph, A. Lang et al. 2004. Levodopa and the progression of Parkinson's disease. N Engl J Med 351:2498-508.
19. Feigin, A., M. G. Kaplitt, C. Tang, T. Lin, P. Mattis, V. Dhawan et al. 2007. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci USA 104:19559-64.
20. Fodero-Tavoletti, M. T., R. S. Mulligan, N. Okamura, S. Furumoto, C. C. Rowe, Y. Kudo et al. 2009. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. Eur J Pharmacol 617:54-8.
21. Follett, K. A., F. M. Weaver, M. Stern, K. Hur, C. L. Harris, P. Luo et al. 2010. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 362:2077-91.
22. Freed, C. R., P. E. Greene, R. E. Breeze, W. Y. Tsai, W. DuMouchel, R. Kao et al. 2001. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344:710-9.
23. Fukuda, M., A. Barnes, E. S. Simon, A. Holmes, V. Dhawan, N. Giladi et al. 2004. Thalamic stimulation for parkinsonian tremor: Correlation between regional cerebral blood flow and physiological tremor characteristics. Neuroimage 21:608-15.
24. Gill, S. S., N. K. Patel, G. R. Hotton, K. O'Sullivan, R. McCarter, M. Bunnage et al. 2003. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9:589-95.
25. Goetz, C. G., J. Wuu, M. P. McDermott, C. H. Adler, S. Fahn, C. R. Freed et al. 2008. Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions. Mov Disord 23:690-9.
26. Gomperts, S. N., D. M. Rentz, E. Moran, J. A. Becker, J. J. Locascio, W. E. Klunk et al. 2008. Imaging amyloid deposition in Lewy body diseases. Neurology 71:903-10.
27. Gupta, D., J. Saini, C. Kesavadas, P. S. Sarma, and A. Kishore. 2010. Utility of susceptibility-weighted MRI in differentiating Parkinson's disease and atypical parkinsonism. Neuroradiology 52:1087-94.
28. Hanyu, H., T. Asano, H. Sakurai, M. Takasaki, H. Shindo, and K. Abe. 2001. Magnetisation transfer measurements of the subcortical grey and white matter in Parkinson's disease with and without dementia and in progressive supranuclear palsy. Neuroradiology 43:542-6.
29. Henchcliffe, C., D. C. Shungu, X. Mao, C. Huang, M. J. Nirenberg, B. G. Jenkins et al. 2008. Multinuclear magnetic resonance spectroscopy for in vivo assessment of mitochondrial dysfunction in Parkinson's disease. Ann N Y Acad Sci 1147:206-20.
30. Hilker, R., A. T. Portman, J. Voges, M. J. Staal, L. Burghaus, T. van Laar et al. 2005. Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry 76:1217-21.
31. Hilker, R., J. Voges, M. Ghaemi, R. Lehrke, J. Rudolf, A. Koulousakis et al. 2003. Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans. Mov Disord 18:41-8.
32. Hilker, R., J. Voges, T. Weber, L. W. Kracht, J. Roggendorf, S. Baudrexel et al. 2008. STN-DBS activates the target area in Parkinson disease: An FDG-PET study. Neurology 71:708-13.
33. Holloway, R. G., I. Shoulson, S. Fahn, K. Kieburtz, A. Lang, K. Marek et al. 2004. Pramipexole vs. levodopa as initial treatment for Parkinson disease: A 4-year randomized controlled trial. Arch Neurol 61:1044-53.
34. Hughes, A. J., S. E. Daniel, L. Kilford, and A. J. Lees. 1992. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-4.
35. Kalbe, E., J. Voges, T. Weber, M. Haarer, S. Baudrexel, J. C. Klein et al. 2009. Frontal FDG-PET activity correlates with cognitive outcome after STN-DBS in Parkinson disease. Neurology 72:42-9.
36. Kaplitt, M. G., A. Feigin, C. Tang, H. L. Fitzsimons, P. Mattis, P. A. Lawlor et al. 2007. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet 369:2097-105.
37. Karimi, M., N. Golchin, S. D. Tabbal, T. Hershey, T. O. Videen, J. Wu et al. 2008. Subthalamic nucleus stimulation-induced regional blood flow responses correlate with improvement of motor signs in Parkinson disease. Brain 131:2710-9.
38. la Fougere, C., G. Popperl, J. Levin, B. Wangler, G. Boning, C. Uebleis et al. 2010. The value of the dopamine D2/3 receptor ligand 18F-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes. J Nucl Med 51:581-7.
39. Landau, W. M. 1990. Clinical neuromythology IX. Pyramid sale in the bucket shop: DATATOP bottoms out. Neurology 40:1337-9.
40. Lang, A. E., S. Gill, N. K. Patel, A. Lozano, J. G. Nutt, R. Penn et al. 2006. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59:459-66.
41. Ma, Y., C. Tang, T. Chaly, P. Greene, R. Breeze, S. Fahn et al. 2010. Dopamine cell implantation in Parkinson's disease: Long-term clinical and (18)F-FDOPA PET outcomes. J Nucl Med 51:7-15.
42. Ma, Y., C. Tang, P. G. Spetsieris, V. Dhawan, and D. Eidelberg. 2007. Abnormal metabolic network activity in Parkinson's disease: Test-retest reproducibility. J Cereb Blood Flow Metab 27:597-605.
43. Maetzler, W., M. Reimold, I. Liepelt, C. Solbach, T. Leyhe, K. Schweitzer et al. 2008. [11C]PIB binding in Parkinson's disease dementia. Neuroimage 39:1027-33.
44. Marks, W. Jr. J., J. L. Ostrem, L. Verhagen, P. A. Starr, P. S. Larson, R. A. Bakay et al. 2008. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase I trial. Lancet Neurol 7:400-8.
45. Marshall, V. L., J. Patterson, D. M. Hadley, K. A. Grosset, D. G. Grosset. 2006. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun 27:933-7.
46. Martin, W. R. W. 2009. Quantitative estimation of regional brain iron with magnetic resonance imaging. Parkinsonism Relat Disord 15 (Suppl 3): S215-18.
47. Obinu, M. C., M. Reibaud, V. Blanchard, S. Moussaoui, and A. Imperato. 2002. Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence. Mov Disord 17:13-9.
48. Oertel, W. H., J. Schwarz, and K. L. Leenders. 2001. Group PS. Results of a 3-year randomized, double blind, PET controlled study of pergolide vs levodopa as monotherapy in early Parkinson's diease PELMOPET trial. J Neurosci 187 (Suppl 1): 444.
49. Oertel, W. H., E. Wolters, C. Sampaio, S. Gimenez-Roldan, B. Bergamasco, M. Dujardin et al. 2006. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord 21:343-53.
50. Olanow, C. W., and O. Rascol. 2010. The delayed-start study in Parkinson disease: Can't satisfy everyone. Neurology 74:1149-50.
51. Olanow, C. W., O. Rascol, R. Hauser, P. D. Feigin, J. Jankovic, A. Lang et al. 2009. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361:1268-78.
52. Parkinson Study Group. 1989a. DATATOP: A multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol 46:1052-60.
53. Parkinson Study Group. 1989b. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321:1364-71.
54. Parkinson Study Group. 2002. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. Jama 287:1653-61.
55. Parkinson Study Group. 2000. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Jama 284:1931-8.
56. Parkinson Study Group CALM Cohort Investigators. 2009. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 66:563-70.
57. Pavese, N., A. H. Evans, Y. F. Tai, G. Hotton, D. J. Brooks, A. J. Lees et al. 2006. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: A PET study. Neurology 67:1612-7.
58. Pavese, N., L. Kiferle, and P. Piccini. 2009. Neuroprotection and imaging studies in Parkinson's disease. Parkinsonism Relat Disord 15 (Supp l 4):S33-7.
59. Pavese, N., O. Rascol, C. W. Olanow, P. Truffinet, and D. J. Brooks. 2005. The effects of riluzole on progression of early Parkinson's disease: An 18F-fluorodopa PET study. Parkinsonism Relat Disord 11 (Supple 2): 229.
60. Piccini, P., N. Pavese, P. Hagell, J. Reimer, A. Bjorklund, W. H. Oertel et al. 2005. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 128:2977-86.
61. Ravina, B., C. Tanner, D. Dieuliis, S. Eberly, E. Flagg, W. R. Galpern et al. 2009. A longitudinal program for biomarker development in Parkinson's disease: A feasibility study. Mov Disord 24:2081-90.
62. Seppi, K., and M. F. Schocke. 2005. An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. Curr Opin Neurol 18:370-5.
63. Smid, L. M., T. D. Vovko, M. Popovic, A. Petric, V. Kepe, J. R. Barrio et al. 2006. The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases. Brain Pathol 16:124-30.
64. Stover, N. P., R. A. Bakay, T. Subramanian, C. D. Raiser, M. L. Cornfeldt, A. W. Schweikert et al. 2005. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Arch Neurol 62:1833-7.
65. Tang, C. C., K. L. Poston, T. Eckert, A. Feigin, S. Frucht, M. Gudesblatt et al. 2010. Differential diagnosis of parkinsonism: A metabolic imaging study using pattern analysis. Lancet Neurol 9:149-58.
66. The Parkinson Study Group PRECEPT Investigators. 2007. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 69:1480-90.
67. Walter, U. 2009. Transcranial brain sonography findings in Parkinson's disease: Implications for pathogenesis, early diagnosis and therapy. Expert Rev Neurother 9:835-46.
68. Watts, R. L., R. E. Gross, R. A. Hauser, R. A. E. Bakay, H. Reichmann, W. Eisner et al. 2009. The STEPS trial: A phase 2b study evaluating spheramine ® in patients with advanced Parkinson's disease. Abstracts of the Movement Disorder Society's Thirteenth International Congress of Parkinson's Disease and Movement Disorders: Presented as late-breaking abstract LB-18.
69. Whone, A. L., R. L. Watts, A. J. Stoessl, M. Davis, S. Reske, C. Nahmias et al. 2003. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54:93-101.